An open, phase I study of cediranib in patients with acute myeloid leukemia (AML)

被引：0
|
作者：
Fiedler, Walter [1 ]
Mesters, Rolf [2 ]
Heuser, Michael [3 ]
Ehninger, Gerhard [4 ]
Ottman, Oliver G. [5 ]
Berdel, Wolfgang E. [2 ]
Zirrgiebel, Ute [6 ]
Robertson, Jane [7 ]
Puchalski, Thomas A. [8 ]
Brave, Sandra R. [7 ]
Juergensmeier, Juliane M. [7 ]
Serve, Hubert [2 ,5 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[2] Univ Hosp, Munster, Germany
[3] Hannover Med Sch, D-3000 Hannover, Germany
[4] Univ Hosp Carl Gustav Carus, Dresden, Germany
[5] Univ Hosp, Frankfurt, Germany
[6] ProQinase GmbH, Freiburg, Germany
[7] AstraZeneca, Macclesfield, Cheshire, England
[8] AstraZeneca, Wilmington, DE USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.895.895
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
895
引用
收藏
页码：273A / 273A
页数：1
相关论文
共 50 条
  • [41] A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia
    Murthy, Guru Subramanian Guru
    Saliba, Antoine N.
    Szabo, Aniko
    Harrington, Alexandra
    Abedin, Sameem
    Carlson, Karen
    Michaelis, Laura
    Runaas, Lyndsey
    Baim, Arielle
    Hinman, Alex
    Maldonado-Schmidt, Sonia
    Venkatachalam, Annapoorna
    Flatten, Karen S.
    Peterson, Kevin L.
    Schneider, Paula A.
    Litzow, Mark
    Kaufmann, Scott H.
    Atallah, Ehab
    HAEMATOLOGICA, 2024, 109 (09) : 2864 - 2872
  • [42] A Phase I Study of Pevonedistat, Azacitidine and Venetoclax for Patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML)
    Murthy, Guru Subramanian Guru
    Kaufmann, Scott H.
    Szabo, Aniko
    Harrington, Alexandra M.
    Michaelis, Laura C.
    Abedin, Sameem
    Carlson, Karen
    Runaas, Lyndsey
    Longo, Walter L.
    Hinman, Alexander
    Maldonado-Schmidt, Sonia
    Thomas, Althea
    Baim, Arielle
    Litzow, Mark R.
    Atallah, Ehab L.
    BLOOD, 2021, 138
  • [43] Clinicopathologic Spectrum of Dermatological Diseases in Patients with Acute Myeloid Leukemia (AML): A Retrospective Study in AML Patients with Cutaneous Manifestations
    Cetinarslan, Tubanur
    Avci, Beyza Ture
    Pehlivan, Fatma Seher
    Aydogdu, Ismet
    Temiz, Peyker
    Ermertcan, Aylin Turel
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2025,
  • [44] A PHASE I TRIAL OF LENALIDOMIDE IN COMBINATION WITH INTERMEDIATE DOSE CYTARABINE (IDC) IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) PATIENTS
    Vigil, E.
    Griffiths, A.
    Thompson, E.
    Brady, E.
    Dickey, M.
    Ford, A.
    Wang, S.
    Wetzler, M.
    HAEMATOLOGICA, 2012, 97 : 33 - 33
  • [45] A phase I trial of CHIR-258, a multitargeted RTK inhibitor, in acute myeloid leukemia (AML)
    Morgan, GJ
    Parker, A
    Cavet, J
    Cavenaugh, J
    Heise, C
    Garzon, F
    BLOOD, 2005, 106 (11) : 783A - 784A
  • [46] A retrospective study of comorbidities and complications in elderly acute myeloid leukemia (AML) patients in the US
    Dhopeshwarkar, Neil
    Wang, Xuehong
    Iqbal, Shahed
    Salas, Maribel
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [47] Evaluation of ON01910.Na In Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I Study
    Silverman, Lewis R.
    Navada, Shyamala C.
    Odchimar-Reissig, Rosalie
    Najfeld, Vesna
    Ohnuma, Takao
    Wilhelm, Francois
    Reddy, E. Premkumar
    Holland, James F.
    BLOOD, 2010, 116 (21) : 1214 - 1214
  • [48] Phase I Study to Assess the Safety and Tolerability of AZD1152 In Combination with Low Dose Cytosine Arabinoside In Patients with Acute Myeloid Leukemia (AML)
    Kantarjian, Hagop M.
    Sekeres, Mikkael A.
    Ribrag, Vincent
    Rousselot, Philippe
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Owen, Kate
    Stockman, Paul
    Oliver, Stuart
    BLOOD, 2010, 116 (21) : 287 - 287
  • [49] Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
    Daver, Naval Guastad
    Kantarjian, Hagop M.
    Pierce, Sherry
    Brandt, Mark
    Dinardo, Courtney Denton
    Pemmaraju, Naveen
    Vaughan, Kenneth
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Borthakur, Gautam
    Kadia, Tapan M.
    Cortes, Jorge E.
    Craig, Adam
    Ravandi, Farhad
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [50] Phase I study of UCN-01 and ara-C for patients with refractory or relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
    Cortes, J
    Plunkett, WK
    Estey, EH
    Keating, MJ
    Madden, T
    Sampath, D
    Faderl, S
    Beran, M
    Dancey, J
    Kantarjian, HM
    BLOOD, 2001, 98 (11) : 211B - 211B
12345